用于指导复发/难治性淋巴瘤药物联合治疗的离体平台
这项前瞻性研究在新加坡两家学术医院纳入71例复发/难治性非霍奇金淋巴瘤患者,采用二次表型优化平台(QPOP)对新鲜活检标本进行离体药物敏感性测试,从有限量肿瘤样本中预测患者特异性药物联合方案。75份样本中67份生成个体化QPOP报告,中位周转时间6天;含copanlisib或romidepsin的双药组合分别对B细胞和NK/T细胞淋巴瘤样本最有效。在无标准方案时由医生酌情给予的标签外QPOP指导治疗(n=17)中观察到5例完全缓解。
要点
- QPOP可在临床可行时间内(中位6天)从有限量活检样本生成个体化药物联合报告。
- 含copanlisib的双药组合对B细胞淋巴瘤样本最有效,含romidepsin的组合对NK/T细胞淋巴瘤样本最有效。
- 无标准方案时经医生酌情给予的标签外QPOP指导治疗(n=17)中观察到5例完全缓解。
核心结论
- 离体分析识别患者特异性药物联合方案在复发/难治性非霍奇金淋巴瘤中于临床可行时间范围内可实现。
- 这些数据为评估离体指导联合治疗的前瞻性临床试验提供了基础。
研究设计与样本
- 前瞻性研究,在新加坡两家学术医院纳入71例复发/难治性非霍奇金淋巴瘤患者(39例B细胞非霍奇金淋巴瘤和32例NK/T细胞非霍奇金淋巴瘤),既往治疗中位线数为2线,入组时间为2017年11月至2021年8月。
- 新鲜活检标本使用12种已知对非霍奇金淋巴瘤有效的药物面板进行离体测试,以识别有效的单药和联合治疗。
- 75份患者样本中67份生成个体化QPOP报告,从样本采集到报告生成的中位周转时间为6天。
主要发现
- 含copanlisib的双药组合对B细胞非霍奇金淋巴瘤样本最有效,含romidepsin的双药组合对NK/T细胞非霍奇金淋巴瘤样本最有效。
- 在无标准方案时由医生酌情给予的标签外QPOP指导治疗(n=17)中,观察到5例完全缓解。
- 在既往治疗超过2线的患者中,QPOP指导治疗的疾病进展率低于传统化疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文报告这些数据为进一步评估离体指导联合治疗的前瞻性临床试验提供了基础。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although combination therapy is the standard of care for relapsed/refractory non-Hodgkin's lymphoma (RR-NHL), combination treatment chosen for an individual patient is empirical, and response rates remain poor in individuals with chemotherapy-resistant disease. Here, we evaluate an experimental-analytic method, quadratic phenotypic optimization platform (QPOP), for prediction of patient-specific drug combination efficacy from a limited quantity of biopsied tumor samples. In this prospective study, we enrolled 71 patients with RR-NHL (39 B cell NHL and 32 NK/T cell NHL) with a median of two prior lines of treatment, at two academic hospitals in Singapore from November 2017 to August 2021. Fresh biopsies underwent ex vivo testing using a panel of 12 drugs with known efficacy against NHL to identify effective single and combination treatments. Individualized QPOP reports were generated for 67 of 75 patient samples, with a median turnaround time of 6 days from sample collection to report generation. Doublet drug combinations containing copanlisib or romidepsin were most effective against B cell NHL and NK/T cell NHL samples, respectively. Off-label QPOP-guided therapy offered at physician discretion in the absence of standard options (n = 17) resulted in five complete responses. Among patients with more than two prior lines of therapy, the rates of progressive disease were lower with QPOP-guided treatments than with conventional chemotherapy. Overall, this study shows that the identification of patient-specific drug combinations through ex vivo analysis was achievable for RR-NHL in a clinically applicable time frame. These data provide the basis for a prospective clinical trial evaluating ex vivo-guided combination therapy in RR-NHL.
引用
- Goh J, De Mel S, Hoppe MM, et al. An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma. Sci Transl Med. 2022. PMID: 36260690. doi:10.1126/scitranslmed.abn7824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。